Neola Medical (NEOLA) Q2 2024 earnings summary

Executive summary

• Achieved key milestones in Q2 2024, including transition to clinical validation phase, successful Human Factors Validation Study in the US, and progress in FDA approval process for a non-invasive neonatal lung monitoring device.

• Established a U.S. subsidiary, intensified US market preparations, and strengthened the board with American expertise to support U.S. market entry.

• Recognized as a Stanford Impact 1 company, received international innovation awards, and won silver at Stanford PDC Accelerator Pitch Competition, enhancing credibility and regulatory support.

• Obtained CB certificate, confirming compliance with international medical device standards.

• Granted European patent for Neola® after the quarter.

Financial highlights

• Operating expenses increased by SEK 1.9 million in H1 2024, mainly due to clinical studies, product development, and team expansion.

• SEK 7.4 million spent on development costs in H1 2024, up SEK 1.4 million year-over-year.

• H1 2024 operating result: SEK -5,579k (H1 2023: -4,941k); EPS: -0.08 SEK (-0.09 SEK).

• Cash and cash equivalents at period end: SEK 29,111k (H1 2023: SEK 30,178k); equity ratio at June 30, 2024: 93%.

• Company valuation exceeded SEK 200 million, doubling since end of 2023.

Outlook and guidance

• Preparing for pivotal clinical study on preterm infants in the U.S., expected to start in H1 2025.

• Plans to submit FDA and CE documentation for Neola® in 2025, with commercial launch dependent on regulatory approvals.

• Anticipates FDA submission after study completion, with potential U.S. market launch in late 2025 or early 2026.

• Expects next milestone to be ethical approval for the U.S. clinical study.

• Cost base expected to rise as product development and commercial preparations accelerate.